Click Here for 5% Off Your First Aladdin Purchase!

ENMD-2076 Tartrate - 99%, high purity , CAS No.1453868-32-0

  • ≥99%
Item Number
E649120
Grouped product items
SKUSizeAvailabilityPrice Qty
E649120-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$120.90
E649120-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$180.90

Basic Description

Synonyms1453868-32-0|KXQ762CQTH|ENMD-2076 Tartrate|ENMD-2076 L-(+)-Tartaric acid|UNII-KXQ762CQTH|ENMD-2076 tartrate|L-(+) Tartrate salt of ENMD-981693|1453868-32-0 (tartrate)|(E)-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine
Specifications & Purity99%
Storage TempStore at 2-8°C,Desiccated
Shipped InWet ice
Product Description

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC 50 s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A , Flt3 , KDR/VEGFR2 , Flt4/VEGFR3 , FGFR1 , FGFR2 , Src , PDGFRα , respectively.

In Vitro

ENMD-2076 is selective toward Aurora A versus Aurora B (IC 50 =350 nM). ENMD-2076 inhibits HUVEC growth with an IC 50 value of 0.15 mM. Against 10 human leukemia cell lines, the IC 50 values range from 0.025 to 0.53 mM. Within this panel, MV4:11 cells are the most sensitive cells by a factor of greater than 4. The lymphoma-derived U937 cell line treated with ENMD-2076 shows that the ENMD-2076 induces a dose-dependent increase in G2-M-phase arrest as well as the induction of apoptosis. ENMD-2076 inhibits cellular Flt3 ligand (FL)-induced Flt3 autophosphorylation in THP-1 cells, which have been shown to express FL-responsive wild-type Flt- 3 (18) with an IC 50 value of 28 nM. ENMD-2076 inhibits stem cell factor (SCF)-induced Kit autophosphorylation in MO7e cells with an IC 50 value of 40 nM. ENMD-2076 inhibits VEGFR2/KDR autophosphorylation with an IC 50 value of 7 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ENMD-2076 treatment results in statistically significant, dose dependent inhibition of tumor growth or tumor regression. Moreover, there is no correlation between tumor growth rate and antitumor efficacy, which would conceivably be expected for a mitotic kinase inhibitor, as fast growing (e.g., A375 melanoma) and slow-growing (e.g., HT29 colon carcinoma) tumors are similarly inhibited by ENMD-2076. ENMD-2076 is well tolerated at daily doses up to 302 mg/kg (equivalent to 200 mg/kg of the free base), with no weight loss or signs of morbidity noted in any study at this dose with the exception of the A375 model . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

IC50& Target:Aurora A 1.86 nM (IC 50 ) KDR 58.2 nM (IC 50 ) Flt-4 15.9 nM (IC 50 ) FGFR1 92.7 nM (IC 50 ) FGFR2 70.8 nM (IC 50 ) PDGFRα 56.4 nM (IC 50 ) Flt3 14 nM (IC 50 )

Names and Identifiers

IUPAC Name (2R,3R)-2,3-dihydroxybutanedioic acid;6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine
INCHI InChI=1S/C21H25N7.C4H6O6/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17;5-1(3(7)8)2(6)4(9)10/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26);1-2,5-6H,(H,7,8)(H,9,10)/b9-8+;/t;1-,2-/m.1/s1
InChi Key KGWWHPZQLVVAPT-STTJLUEPSA-N
Canonical SMILES CC1=CC(=NN1)NC2=CC(=NC(=N2)C=CC3=CC=CC=C3)N4CCN(CC4)C.C(C(C(=O)O)O)(C(=O)O)O
Isomeric SMILES CC1=CC(=NN1)NC2=CC(=NC(=N2)/C=C/C3=CC=CC=C3)N4CCN(CC4)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
Alternate CAS 1453868-32-0
PubChem CID 24776050
Molecular Weight 525.56

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Chemical and Physical Properties

SolubilityDMSO : 25 mg/mL (47.57 mM; Need ultrasonic)

Related Documents

Solution Calculators